Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Antiviral Res. 2016 May 13;132:26–37. doi: 10.1016/j.antiviral.2016.05.005

Figure 6. Assessment of antiviral drugs in HepBHAe82 cells.

Figure 6

(A) Schematics of HBV replication steps and antiviral targets in HepBHAe82 cells. (B) Upon withdrawal of tet, HepBHAe82 cells were treated with Bay41-4109 (2 µM), AT-61 (25 µM), and 3TC (10 µM) for 6 days. The compound treatment was repeated every two days. Intracellular viral RNA, core protein, capsid particles, encapsidated pgRNA, and core DNA, were analyzed.